tobramycin 0.003 MG/MG Ophthalmic Ointment [Tobrex]

What the CMS Formulary Data Shows for tobramycin 0.003 MG/MG Ophthalmic Ointment [Tobrex]

Per the CMS 2026 Part D formulary file, tobramycin 0.003 MG/MG Ophthalmic Ointment [Tobrex] (RxNorm concept RXCUI 207850, generic name tobramycin) appears on 26 distinct formulary files spanning 490 Medicare Part D plan offerings - 9.7% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 2 to Tier 4, with a cross-plan average of Tier 3.5.

Real-world access to tobramycin 0.003 MG/MG Ophthalmic Ointment [Tobrex] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 195,319 Part D beneficiaries filled tobramycin 0.003 MG/MG Ophthalmic Ointment [Tobrex] in 2023, with total plan-and-beneficiary spending of $2,165,446 and an average per-beneficiary annual cost of $11.09. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry tobramycin 0.003 MG/MG Ophthalmic Ointment [Tobrex] today.